resminostat + sorafenib

Resminostat + sorafenib is a **combination therapy** of two small molecule drugs, resminostat and sorafenib, investigated in clinical trials primarily for the treatment of advanced hepatocellular carcinoma (HCC). **Resminostat** is an oral inhibitor of class I, IIb, and IV histone deacetylases (HDAC), which modulates gene expression through epigenetic mechanisms and affects cancer cell differentiation, proliferation, and survival. **Sorafenib** is a multikinase inhibitor targeting RAF serine/threonine kinases and several growth factor receptor tyrosine kinases involved in angiogenesis and tumor cell proliferation. The combination is designed to overcome resistance to sorafenib and target cancer through both epigenetic modulation and inhibition of oncogenic signaling pathways. In clinical trials, the combination was generally well tolerated, but did not significantly improve primary survival endpoints versus sorafenib alone in unselected populations. Some benefit was noted in genetic or platelet-based subgroups[1][2][3][6].

Brand names

Nexavar

Other names

resminostat + sorafenib